Skip to content

Tritanium® Study in Japan

The Verification Study on the Early Fixation/ Stability of Tritanium Cup

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02552069
Enrollment
50
Registered
2015-09-16
Start date
2015-06-30
Completion date
2020-03-31
Last updated
2018-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Avascular Necrosis of the Femoral Head, Osteoarthritis, Rheumatoid Arthritis

Brief summary

The purpose of this study is to evaluate early fixation and stability of the Tritanium cup. It is expected that the Tritanium® cup will be equal to or better than conventional cementless cups in early fixation/stability and meet the expectations of Japanese surgeons.

Interventions

DEVICETritanium® cup

Sponsors

Stryker Japan K.K.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient is a candidate for a primary Total Hip Arthroplasty (THA). 2. Patient who has diagnosis of secondary osteoarthritis, avascular necrosis and rheumatoid arthritis. 3. Patient whose age is 20 or over. 4. Patient who signed an Institutional Review Board (IRB)-approved, study specific Informed Patient Consent Form. 5. Patient who is willing and able to comply with postoperative scheduled evaluations.

Exclusion criteria

1. Patient who has a bacterial infectious disease or has a high risk of a bacterial infection. 2. Patient who requires revision surgery of a previously implanted total hip arthroplasty. 3. Patient who is morbidly obese, defined as having a Body Mass Index (BMI) \> 40. 4. Patient who is or may be pregnant female. 5. Patient who has neuromuscular or neurosensory deficiency, which limits ability to evaluate the safety and efficacy of the device. 6. Patient with diagnosed systemic disease (i.e. Paget's disease, renal osteodystrophy), which limits ability to evaluate the safety and efficacy of the device. 7. Patient who is immunologically suppressed or receiving chronic steroids, which limits ability to evaluate the safety and efficacy of the device. 8. Patients who is judged ineligible with specific reason by primary doctor.

Design outcomes

Primary

MeasureTime frame
Change in implantation position(angle) of the cupBaseline, intraoperative, 3 months, 6 months and 12 months

Secondary

MeasureTime frame
Change in Japanese Orthopaedic Association (JOA) scoreBaseline, 3 months, 6months and 12 months
Change in Quality of Life as assessed by Euro QOL 5 Dimension (EQ-5D)Pre-operation, 3 months, 6months and 12 months

Countries

Japan

Contacts

Primary ContactYsuyuki Inatsugu
yasuyuki.inatsugu@stryker.com+81-3-6894-8394

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026